Bioequivalence study as component of the pharmaceutical development for the Azithromycin capsules 500 mg.
Keywords:
pharmaceutical development, bioequivalence dissolution testing, azithromycin
Abstract
Pharmaceutical development is carried out and the medicine Azithromycin, capsules 500 mg introduced into production. The medicine is equivalent to the reference preparation, which was registered in Ukraine, in accordance with the requirements of the Investigation of Bioavailability and Bioequivalence.
References
1. Regulation 42-3.1.2004. Guidance on quality. Medicines. Pharmaceutical development.
2. Regulation 42-7.1.2005. Guidance on quality. Research on bioavailability and bioequivalence.
3. Shklyaev SA, Tsurkan OO, Kolyadych O.P., Kulikova O.O. // Pharmaceutical Journal. - 2010. - No. 6 - P. 50-55.
4. Shklyaev S.A., Tsurkan O.O., Kolyadych O.P., Kulikova O.O. // Pharmaceutical Journal. - 2011. - No. 1 - P. 64-68.
2. Regulation 42-7.1.2005. Guidance on quality. Research on bioavailability and bioequivalence.
3. Shklyaev SA, Tsurkan OO, Kolyadych O.P., Kulikova O.O. // Pharmaceutical Journal. - 2010. - No. 6 - P. 50-55.
4. Shklyaev S.A., Tsurkan O.O., Kolyadych O.P., Kulikova O.O. // Pharmaceutical Journal. - 2011. - No. 1 - P. 64-68.
Published
2019-03-18
How to Cite
Shkliaiev, S., & Kulikova, O. (2019). Bioequivalence study as component of the pharmaceutical development for the Azithromycin capsules 500 mg. Farmatsevtychnyi Zhurnal, (1), 49-53. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/550
Section
Original Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
